NCT03185039Active, not recruiting
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic (Localized Kidney Cancer and Oligometastatic)
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or Pazopanib).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 9 Jun 2017
- Start date
- 29 May 2017
- Primary completion date
- 19 Dec 2026
- Lead sponsor
- Institut Paoli-Calmettes
- Diseases
- Kidney cancer
- NCT number
- NCT03185039
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 29 May 2017 to the primary completion date, 19 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient previously treated with anti-angiogenic agents.
Other illness
- Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons 4. History of malignant disease in the 5 years prior to inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in situ, or prostate cancer with a good prognosis (stage T \<3 and Gleason \<7)) accidentally discovered during the histological analysis of the tumor sample.
- 5- Pregnant or nursing women 6- Contraindications to the procedure of the study
Other
- Person in an emergency situation, adult subject to a legal protection measure (a guardian, guardianship or safeguard of justice), or unable of expressing his / her consent.
Who the study is looking for
- Patient male or female, aged of more than 18 years
- Patient with any of the following conditions:
- Kidney cancer localized at diagnosis.
- Metastatic kidney cancer when anti-angiogenic therapy is initiated by Sunitinib or Pazopanib
- Oligometastatic kidney cancer without systemic treatment (local treatment)
- ECOG = 0 to 2
- Patient affiliated to, or beneficiary of, the national social security.
- Patient having signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.